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A B S T R A C TBackground: Every Woman Counts (EWC), a California breast cancer
screening program, faced challenging budget cutbacks and policy
choices. Methods: A microsimulation model evaluated costs, out-
comes, and cost-effectiveness of EWC program mammography policy
options on coverage for digital mammography (which has a higher
cost than ﬁlm mammography but recent legislation allowed reim-
bursement at the lower ﬁlm rate); screening eligibility age; and
screening frequency. Model inputs were based on analyses of program
claims data linked to California Cancer Registry data, Surveillance,
Epidemiology, and End Results data, and the Medi-Cal literature.
Outcomes included number of procedures, cancers, cancer deaths,
costs, and incremental cost per life-year. Results: Projected model
outcomes matched program data closely. With restrictions on the
number of clients screened, strategies starting screening at age 40
years were dominated (not cost-effective). This ﬁnding was highly
robust in sensitivity analyses. Compared with no screening, biennial
ﬁlm mammography for women aged 50 to 64 years was projected to
reduce 15-year breast cancer mortality by nearly 7.8% at $18,999 persee front matter Copyright & 2013, International S
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, Sacramento, CA 95817.additional life-year, annual ﬁlm mammography was $106,428 per
additional life-year, and digital mammography $180,333 per addi-
tional life-year. This more effective, more expensive strategy was
projected to reduce breast cancer mortality by 8.6%. Under equal
mammography reimbursement, biennial digital mammography
beginning at age 50 years was projected to decrease 15-year breast
cancer mortality by 8.6% at an incremental cost per additional life-
year of $17,050. Conclusions: For the EWC program, biennial screen-
ing mammography starting at age 50 years was the most cost-
effective strategy. The impact of digital mammography on life expect-
ancy was small. Program-speciﬁc cost-effectiveness analysis can be
completed in a policy-relevant time frame to assist policymakers
faced with difﬁcult program choices.
Keywords: breast cancer screening, cost-effectiveness analysis, health
policy, safety net programs.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cost-effectiveness analysis (CEA) allows policymakers and others
to consider the potential impacts of alternative policies on future
program outcomes and costs. As demands escalate on the health
care system to provide more services within constrained budgets,
CEA is a technique that can enable policymakers to examine the
value of health care services [1]. Although well established for
providing guidance to policymakers in many arenas, CEA has
been slow to take hold in United States health policy [2]. Health
care resources, particularly those for safety net programs, are
increasingly limited, and carefully constructed CEA models can
inform resource allocation decisions.
While CEA has considerable potential to assist makers of
health policy, a number of challenges confront its application to
health policy formulation. Models often take the perspective of
society in accounting for program impacts, but for public health
programs, the perspective of the payer is also highly relevant [3].
The generalizability of models is often curtailed by assumptionsembedded within the model that may not be relevant to public
health program or policy needs [4]. Timeliness is another chal-
lenge confronting the adoption of CEA; historically, cost-
effectiveness results have been published too late to inﬂuence
health policy decisions [5].
To use CEA more effectively to inform health policy, we
worked with a state safety net breast cancer screening program
to conduct a program-speciﬁc CEA, based on program data and
addressing policy questions posed by program administrators.
California’s Cancer Detection Programs: Every Woman Counts (EWC)
was administered through the state Department of Public Health
Cancer Detection Section. It is funded jointly by state tobacco tax
dollars and federal funds administered through the Centers for
Disease Control and Prevention National Breast and Cervical
Cancer Early Detection Program. One of the largest of all 68
Centers for Disease Control and Prevention–funded programs,
EWC reimburses public and private providers at Medi-Cal rates
for screening and diagnostic services for breast and cervical
cancers. Medi-Cal is the California version of Medicaid, a jointociety for Pharmacoeconomics and Outcomes Research (ISPOR).
licy and Research, University of California, Davis, 2103 Stockton
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income individuals who meet eligibility criteria. California
women not eligible for Medi-Cal whose income is less than
200% of the federal poverty threshold who also lack adequate
coverage for breast and cervical cancer screening are eligible to
enroll in the EWC program.
Our study focused exclusively on the breast cancer screening
program, which largely served women aged 40 to 64 years with
both screening and diagnostic evaluations. Like many public
health programs, the program budget was limited. Program staff
estimated that the program served approximately 40% of low-
income, uninsured women 40 years and older. Declining tax
revenues combined with increased demand for services created
intense budgetary pressure on the program. At the same time,
digital mammography, not included in the program because of
higher cost, was diffusing throughout the state. Program staff
were concerned that EWC program clients might have reduced
access to screening in some areas because of rapid provider
adoption of this newer technology. Digital mammography
requires a large initial investment in equipment, but eliminates
the need for ﬁlm storage and enables the digital manipulation of
images. It is reimbursed by Medi-Cal at a rate about double that of
ﬁlm mammography. A large US trial evaluating the diagnostic
accuracy of digital compared with ﬁlm mammography found
overall similar performance for the two modalities; however,
digital mammography performed slightly better in women
younger than 50 years [6]. After the project began, Assembly Bill
359 permitted digital mammography providers to bill the EWC
program and be reimbursed at the Medi-Cal ﬁlm mammography
rate beginning January 1, 2010. This legislation will expire in 2014,
and if it is not renewed, the program will then be required to pay
the higher rate for digital mammograms or limit EWC program
clients to ﬁlm mammography only.
The age to begin regular screening mammography and the
interval for screening were additional areas of program policy
concern, due to limited resources and scientiﬁc controversy [7–
13]. Randomized trials have demonstrated a relative reduction of
about 15% in breast cancer mortality from screening mammog-
raphy among women aged 40 to 59 years, but women aged 40 to
49 years have a lower absolute risk reduction due to a lower
incidence of breast cancer [14]. This age group also has a higher
rate of false-positive mammograms [13,14]. Interpretations of theFig. 1 – Micro-simulation model overview. (Proportions of undiagnoevidence and resulting recommendations for the age to start
screening differ across countries and between guidelines [15–20].
Recommended screening intervals are another area in which
evidence is uncertain and recommendations differ [21,22].
Our analysis, based on conversations with program personnel,
focused on three key policy questions:1.sedWhat would be the projected program costs and outcomes
should the EWC program begin reimbursing for digital
mammography?2. What would be the effect on projected program costs and
outcomes of starting screening at age 50 years in place of age
40 years?3. What would be the effects on costs and outcomes of screening
every 2 years in place of the current annual screening policy?Methods
Model Structure
A microsimulation model was developed in TreeAge Pro (TreeAge
Software, Williamstown, MA) to estimate population-level effects
associated with breast cancer screening and diagnosis for women
enrolled in the EWC program, while at the same time accounting
for individual variation in age-related mammography diagnostic
characteristics and breast cancer risk, as well as allowing tracking
of women in the cohort with undiagnosed breast cancer. Analysis
of EWC program claims data provided model inputs including
client age and race-ethnicity distributions, status-speciﬁc tran-
sition probabilities between follow-up diagnostic procedures, and
costs for screening and diagnosis.
The model structure is illustrated in Figure 1. EWC clients
entering the model included women with no cancer and those
whose cancer was undiagnosed. Women with abnormal screen-
ing test results received follow-up diagnostic testing. Women
began treatment when breast cancer was conﬁrmed by either
core needle biopsy or open biopsy. New incident cancer cases and
those missed by the previous screening or follow-up diagnostic
tests presented clinically as interval cancers between screening
rounds or were detected at the subsequent screen.cancer and incident cancer exaggerated for demonstration.)
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choices related to three factors: 1) mammography type (ﬁlm
mammography vs. digital), 2) age of screening initiation (40 vs. 50
years), and 3) screening frequency (annual vs. biennial). All strat-
egies were evaluated under the assumption of 1) equal reimburse-
ment for ﬁlm and digital mammography (currently allowed by
legislation) and 2) standard Medi-Cal (higher) reimbursement for
digital mammography anticipated for 2014. The reference standard
for the model was no screening because women eligible for this
safety net program lack insurance coverage or sufﬁcient income to
pay for breast cancer screening. The model simulated a 5-year
program; outcomes and related costs were analyzed over a 15-year
time horizon. We chose the 5-year implementation period for its
relevance to public policy planning. The 15-year period for screen-
ing outcomes was chosen to better evaluate the long-term effects of
the short-term policy decision because effects of mammography on
breast cancer mortality were shown after median follow-up of 12 to
16 years in randomized controlled trials [23].
A hypothetical cohort of 100,000 women with an age distribu-
tion based on EWC program clients was followed over 15 years in
each simulation. The model simulated the history of each cohort
member during this period, based on age-speciﬁc breast cancer
incidence and mortality rates, using age- and strategy-speciﬁc
input parameters for the sensitivity and speciﬁcity of mammog-
raphy. To address the challenge of a limited program budget, we
assumed that the same number of women in the cohort could
undergo screening mammography whether the strategy began
screening at age 40 years or age 50 years. For strategies beginning
at age 50 years, all 50- to 64-year-olds (56% of the cohort) under-
went screening during the program period, while the 40- to 49-
year-olds had no screening. For strategies beginning screening at
age 40 years, 56% of all cohort members underwent screening,
while 44% of cohort members did not. An unrestricted version of
the model was run for comparison. Age-speciﬁc breast cancer
incidence was weighted on the basis of race-ethnicity distribution
of EWC program clients. Transition probabilities for diagnostic
testing to evaluate abnormal screening results were derived from
the analysis of EWC program claims data.
To assess ﬁrst-order uncertainty, 60 simulations were run to
calculate means and standard errors of model output values.
Eight strategies were run in parallel each time, which meant that
same sampled input values were used across strategies to ensure
counterfactual comparison. Costs and outcomes were discounted
annually at 3%. The incremental cost-effectiveness ratios (ICERs)
were calculated by using the “ratio of means” approach [24].
Model Parameters
Model parameters were obtained from analyses of EWC program
claims, California Cancer Registry data linked to the EWC pro-
gram, Surveillance, Epidemiology and End Results data, and the
published literature. Model parameters are shown in Table 1.
Parameters derived from EWC Program Claims Data Analysis
We analyzed EWC program claims from 2006 to 2009 linked with
California Cancer Registry data to inform model input parameters
for age and race-ethnicity distributions of EWC program clients,
screening and diagnosis costs, the relative frequency of abnormal
results from screening mammography, and transition probabil-
ities between possible options for subsequent diagnostic proce-
dures. A total of 336,115 women aged 40 years and older enrolled
in the EWC program in the period 2006 to 2009 underwent
screening mammography at least once. The mean age of women
screened was 52 years. During this period, the program provided
519,846 screening mammograms, 131,494 diagnostic mammo-
grams, and 15,496 biopsies (1,377 ﬁne needle biopsies, 10,725 core
needle biopsies, and 3,394 open biopsies). In the 1-year follow-upperiod following screening, cancer detection rates were 278
cases/100,000 woman-years in women aged 40 to 64 years
and 326 cases/100,000 woman-years in women aged 50 to
64 years.
Other Model Parameters
Other model parameters, including those describing screening
and diagnostic test characteristics, are listed in Table 1. Preva-
lence rates of breast cancer in the hypothetical cohort (deﬁned as
the proportion of women with breast cancer present at the initial
time point of the policy implementation period) were derived
from the linked EWC program claims-California Cancer Registry
data, and adjusted for the estimated undetected proportion of
breast cancer (based on the age-speciﬁc sensitivity of digital or
ﬁlm mammography). Age-speciﬁc breast cancer incidence rates
and mortality by year since diagnosis were estimated on the basis
of Surveillance, Epidemiology, and End Results (SEER 17 Registries
database) data [30] adjusted for the race-ethnicity distribution of
EWC program clients.
Breast cancers were categorized into three groups depending on
cancer detection: screen-detected cancer, interval breast cancer, and
cancer detected in the absence of a screening program. Interval
breast cancers were deﬁned as histologically proven breast cancers
detected in women with a previous negative screening test result,
during the interval between screening rounds. Interval cancers have
been reported to be more aggressive and to have a worse prognosis
compared with the overall behavior of cancers detected in the
absence of screening [31–33]. Relative to screen-detected cancer, we
assigned 1.39 as the relative mortality risk for interval breast cancer
and 1.30 as the relative risk for cancers detected in the absence of a
screening program [23]. Longer screening intervals lead to a higher
probability for breast cancer to be detected because of presentation
with symptoms rather than by mammographic detection at an
asymptomatic phase. Biennial screening has a higher interval cancer
incidence rate between 13 and 24 months after a previous mammo-
gram than during the ﬁrst 12 months [32,34]. Proportions of interval
cancer cases were adjusted on the basis of the screening interval.
Age group–speciﬁc sensitivity and speciﬁcity for digital and
ﬁlm mammography were derived from the largest comparative
study of digital and ﬁlm mammography conducted in the United
States [6]. The age distribution of that study population differed
from the age distribution in the EWC program, and subgroup
analysis of the trial suggested that digital mammography per-
forms differently in different age groups [26]. To assess the
impact of digital mammography’s sensitivity and speciﬁcity in
age groups conforming to the EWC program, age group–speciﬁc
estimates of sensitivity and speciﬁcity were derived. The sensi-
tivity and speciﬁcity of ﬁne needle biopsy and core needle biopsy
were based on the medical literature [27,28]; open biopsies were
assumed to be the reference standard.
Costs
We included direct costs to the screening program for screening
mammography and professional interpretation, follow-up diag-
nosis costs incurred by abnormal test outcomes, and, for women
diagnosed with breast cancer, costs of treatment (surgeries and
medical costs in the following years). Treatment costs accrue to a
separate breast cancer treatment program, not the EWC program,
but treatment access is required for screening to be effective, and
the treatment program is also funded by state and federal
revenues. Indirect costs were not included. Program costs for
ﬁlm mammography and diagnostic procedures including diag-
nostic mammography, ultrasound, ﬁne needle aspiration, core
needle biopsy, and open breast biopsy were based on average
claims payments by the EWC program for these procedures. Pay-
ments for associated charges (e.g., core needle biopsy and pathology)
Table 1 – Breast cancer screening program model parameters.
Parameters Values Source
Population characteristics of breast cancer
Age distribution (%) EWC program claims data
40–44 y 20.7
45–49 y 22.9
50–54 y 22.7
55–59 y 19.4
60–64 y 14.3
Breast cancer prevalence rate (%) EWC program claims data
40–49 y 0.2301
50–64 y 0.3568
Breast cancer incidence rate (%) SEER-AJCC weighted by EWC program
race-ethnicity proportions40–44 y 0.099
45–49 y 0.152
50–54 y 0.184
55–59 y 0.226
60–64 y 0.264
Age group (y)
Breast cancer mortality rate (%) 40–49 50–64 SEER-AJCC mortality rates over 10 y weighted
by EWC program cancer stage and age distributionsYear 1 1.05 1.26
Year 2 1.82 2.23
Year 3 1.52 2.02
Year 4 1.48 1.76
Year 5 1.28 1.51
Year 6 0.92 1.38
Year 7 0.91 1.14
Year 8 0.75 1.03
Year 9 0.38 1.05
Year 10 0.78 1.01
Relative risks of breast cancer death
Interval cancer vs. screen-detected cancer 1.39 [23]
Cancer in the absence of screening vs. screen-detected
cancer
1.30 [23,25]
Accuracy of screening and diagnostic procedures
Age group (y)
Screening mammography (%) 40–49 50–64 [26] weighted average of subgroup estimates
Sensitivity, digital 68.1 52.7
Sensitivity, ﬁlm 44.5 49.7
Speciﬁcity, digital 90.2 92.5
Speciﬁcity, ﬁlm 90.1 92.3
Diagnostic mammography [6]*
Ratio of sensitivity relative to screening
mammography
1.15
Ratio of speciﬁcity relative to screening
mammography
0.98
FNA result, given having cancer (%) [27]
Normal 2.6
Suspicious 17.0
Abnormal 80.4
FNA result, given not having cancer (%) [27]
Normal 77.7
Suspicious 20.8
Abnormal 1.5
Core needle biopsy (%) [28]
Sensitivity 90.2
Speciﬁcity 1000.0
Open biopsy (%) Reference standard
Sensitivity 100.0
Speciﬁcity 100.0
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Table 1 – continued
Parameters Values Source
Transition probabilities between procedures
Age group (y)
40–49 50–64
From abnormal screening mammography to: EWC program claims data
Open biopsy 0.93 0.70
Core needle biopsy 2.04 1.74
Fine needle aspirate 0.49 0.26
Diagnostic mammography 96.53 97.29
From abnormal diagnostic mammography to:
Open biopsy 15.07 11.74
Core needle biopsy 77.42 82.03
Fine needle aspirate 7.50 6.24
From suspicious ﬁne needle aspirate to:
Open biopsy 86.24 97.83
Additional ﬁne needle aspirate 13.75 2.17
From abnormal core needle biopsy to:
Open biopsy 40.60 26.17
Costs for screening, diagnosis, and treatment of breast cancer†
Routine screening ($)
Routine mammogram (digital) 127.2 Medi-Cal
Routine mammogram (ﬁlm) 66.8 EWC program claims data
Follow-up procedures ($)
Diagnostic mammogram (digital) 133.0 Medi-Cal
Diagnostic mammogram (ﬁlm) 99.4
Open biopsy 444.0 EWC program claims data
Core needle 471.8
Fine needle aspirate 188.2
Breast cancer treatment by year from diagnosis‡ Medicare Reimbursement [29]
Year 1 19,000.5
Year 2 1,238.8
Year 3 983.0
Years 4–10 cost per year 933.2
EWC, Every Woman Counts; FNA, ﬁne needle biopsy; SEER-AJCC, Surveillance, Epidemiology and End Results-American Joint Committee on
Cancer.
 Sensitivity-speciﬁcity based on mammography receiver operator curves (Fig. 1A of Pisano et al. [6]).
† Bundled costs include professional and facility claims.
‡ Bundled cost based on EWC program stage distribution
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 3 2 – 9 4 1936were bundled to obtain an average payment for all elements in that
care episode. Costs of digital and ﬁlmmammography were based on
Medi-Cal reimbursement rates used by the EWC program. Costs for
breast cancer treatment by year since diagnosis were based on
previously developed clinical pathways using Medicare reimburse-
ment rates [29]. In two separate analytical models, costs for digital
mammography screening were set (under current law) as equivalent
to the average claim paid for screening ﬁlm mammography ($67)
and as the Medi-Cal reimbursement rate for digital mammography
($127), respectively. All cost units were adjusted to 2007 dollars.
Model Calibration
The model was calibrated by comparing predicted numbers of
screening mammograms, procedures, and cancer detection rates
for a hypothetical cohort of 100,000 women screened annually for
2 years to actual ﬁndings in the claims data for 40- to 64-year-old
and 50- to 64-year-old age groups during 2006 to 2008. Projected
values corresponded closely to actual values.
Sensitivity Analysis
To analyze the effect of underlying uncertainty of values for key
parameters used in the model, we conducted one-way sensitivityanalyses by varying a single parameter or bundle of parameters (the
cancer-year–speciﬁc mortality rates and treatment costs from year 1
to year 10). We considered a range for underlying breast cancer
incidence, prevalence, and mortality, prognosis of non–screen
detected cancers, mammography test sensitivity and speciﬁcity, costs
of mammography, and costs of breast cancer treatment. We also
varied the discount rate from 1% to 5%. The change in ICERs based on
60 simulation rounds was calculated by using the ratio of means
approach [24). If both mean costs and mean life-year gains were not
statistically different (based on two-tailed t test, with α¼ 5%] from the
base-case values, the differences were considered to be due to
random variation and the base-case ICERs were reported. A scenario
analysis was used to evaluate lack of adherence to mammography
screening. Probabilistic sensitivity analysis was not feasible in this
microsimulationmodel because of very high computational intensity.
Model Assumptions
All models are based on underlying assumptions that determine
how the model is structured. The EWC program model was based
on four key assumptions:1. In the base-case model, the limited program budget enabled
only a ﬁxed number of women to be screened in each year no
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of women was screened in the 40- to 64-year screening strategy
and in the 50- to 64-year screening strategy. While not ﬁxing
costs for the program, this assumption addressed the often
difﬁcult budgetary realities of public health programs. This
assumption was removed in the comparison model.2. EWC program clients in the hypothetical cohort were adherent
to the screening schedule speciﬁed in that particular scenario. It
is extremely difﬁcult to document the actual screening adher-
ence in this program because many women leave the program
when they become eligible for Medi-Cal or gain private insur-
ance; hence, lack of return for a scheduled repeat mammogram
cannot be interpreted as lack of adherence. We conducted a
sensitivity analysis to evaluate the impact of this assumption.3. Digital and ﬁlm mammography were equally accessible to
EWC program clients.4. No changes in outcomes or costs of breast cancer treatment
were projected for the time period of the model.
Results
Base-Case Model
During the 15-year cohort follow-up, the simulation model pro-
jected between 1000 and 1100 total breast cancers. Projected
screen-detected breast cancer rates were higher when screening
was limited to the 50- to 64-year-old age group. Digital mammog-
raphy modestly increased screen-detected cancers than did ﬁlm
mammography, with larger differences when women in the 40- to
49-year age group were screened. The 5-year program costs for
screening and diagnosis in the cohort of 100,000 women ranged
from $13 million to $21 million under the scenario of equal
reimbursement for ﬁlm and digital mammography, and increased
to between $23 million and $37 million for digital mammography
reimbursed at the standard Medi-Cal rate. Appendix Table A1 (in
Supplemental Materials found at: http://dx.doi.org/10.1016/j.jval.
2013.06.013) shows the projected procedures, cancers, and total
costs for a 5-year program period. Table 2 shows the per-person
total costs (including screening, diagnosis, and treatment), life
expectancy, incremental costs, incremental life expectancy, and
incremental cost-effectiveness ratios of alternative screening strat
egies for ﬁlm and digital mammography compared with no screen
ing. These outcomes were projected over a 15-year period to
capture the effects of screening on breast cancer mortality. We
chose no screening as a comparison because if no safety net
program were available, this population would have little or no
access to screening. In the model restricted to a ﬁxed number of
clients, all strategies initiating screening at age 40 years were
dominated (more costly and less effective, or more costly for the
same effectiveness). In the unrestricted model, which assumed
that program funds were available to screen all eligible clients in
the cohort, under standard differential reimbursement for digital
and ﬁlmmammography, biennial ﬁlmmammography beginning at
age 50 years was the least expensive cost-effective option, at
$18,999 per additional life-year. Screening strategies beginning at
age 40 years also had ICERs that could be considered cost-effective,
at $84,607 per additional life-year for biennial digital mammogra
phy and $95,068 per additional life-year for annual digital mam
mography (see Appendix Table A2 in Supplemental Materials
found at: http://dx.doi.org/10.1016/j.jval.2013.06.013).
When digital and ﬁlm mammography were reimbursed at the
same rate, ﬁlmmammography strategies were dominated. Biennial
digital mammography screening for women in the age 50 to 64
years cohort was projected to reduce cancer mortality by 8.6% and
had an incremental cost per additional life-year of $17,050. Annual
screening added to mean life expectancy (0.0069 life-years) at
higher costs, with an incremental cost per additional life-year of$81,666. Under the assumption of standard Medi-Cal (higher)
reimbursement for digital mammography, biennial ﬁlm mammog-
raphy for women aged 50 to 64 years was projected to reduce breast
cancer mortality by nearly 7.8%, at $18,999 per additional life-year.
Annual ﬁlm mammography added to mean life expectancy at
$106,428 incremental cost per additional life-year, and annual
digital mammography incremental cost per additional life-year
was $180,333. The corresponding cost-effectiveness scatter plots
for all strategies under equal reimbursement and standard reim-
bursement rate for digital mammography are shown in Figure 2.
Sensitivity Analyses
In one-way sensitivity analyses, compared with starting screening
at age 40 years, initiating screening for women at age 50 years was
always a dominant strategy (less costly and more effective, or less
costly for the same effectiveness) in the restricted model. Hence,
the ﬁnding of greater cost-effectiveness if the EWC program
limited screening to this age group was highly robust. We did
encounter variability in whether digital or ﬁlm mammography
was an optimal strategy. Assuming equal mammography costs to
the program, decreasing speciﬁcity of digital mammography by
5%, or increasing speciﬁcity of ﬁlm mammography by 5% reversed
the advantage of digital mammography over ﬁlm. Considering the
intrinsic uncertainty of the differences in speciﬁcity between ﬁlm
and digital mammography, results regarding the optimal mam-
mography modality should be interpreted with caution.
We examined the effect of lack of adherence to screening
mammography by modeling an annual dropout rate of 10%, 30%,
and 50%, assuming no further mammography screening in the
program period. As the dropout rate increased, the ICER for
biennial screening using digital mammography from age 50 years
(as compared with no screening) decreased (from $17,050 to $9,788
per additional life-year), suggesting higher cost-effectiveness of
any screening compared with no screening at lower adherence
rates. In contrast, the ICER for annual screening with digital
mammography from age 50 years (as compared with biennial
screening using digital mammography from age 50 years)
increased (from $81,666 to $121,465 per additional life-year),
suggesting that annual screening became less cost-effective as
compared with biennial screening when the adherence rate
dropped. Results of sensitivity analyses are shown in Table 3.Discussion
This program-based cost-effectiveness model illustrated the
potential consequences of policy choices for the EWC program.
Unless funding is available to screen the full population of
eligible women beginning at age 40 years, starting routine screen-
ing at age 50 years is strongly supported by the model results.
This policy maximized the cost-effectiveness of mammography
screening for this budget-constrained program. This ﬁnding is
not surprising, given that women aged 50 years and older have a
higher incidence and prevalence of breast cancer; hence, screen-
ing in this group will yield more early stage cancers and fewer
false-positive results. Because of limited program resources, full
coverage of eligible women has not been achieved for any age
group. Using available resources to maximize access for women
aged 50 to 64 years would have the greatest impact on breast
cancer early detection and breast cancer mortality. Screening
every 2 years captures most of the beneﬁt of annual screening
and could allow more eligible women to be served. This ﬁnding is
consistent with that of other models of breast cancer screening
using different approaches and assumptions [35,36].
The impact of digital mammography on life expectancy is
small and cannot be precisely estimated, but there is likely
Table 2 – Costs, life expectancy, incremental costs, incremental life expectancy, incremental cost-effectiveness
ratios, and cancer mortality reduction for alternative screening strategies, compared with no screening
(reference strategy).
15-y cost*
per person
(2007 $)
15-y life
expectancy (y)
Incremental
costs
(2007 $)
Incremental
life- years
gained (y)
Incremental CE
ratio ($ per
additional life-
year)
Projected
reduction in
breast cancer
mortality† (%)
Equal reimbursement for digital and ﬁlm mammography
No
screening
283.9 (16.1) 11.6783 (0.0010)
Biennial,
40–64, ﬁlm
383.7 (20.6) 11.6813 (0.0012) 99.8 (8.6) 0.0030 (0.0005) – 6.2 (1.3)
Biennial,
50–64, ﬁlm
384.6 (22.2) 11.6836 (0.0011) 100.7 (7.7) 0.0053 (0.0004) – 7.8 (1.3)
Biennial,
50–64, digital
386.2 (22.8) 11.6843 (0.0010) 102.3 (8.5) 0.0060 (0.0005) $17,050 8.6 (1.4)
Biennial,
40–64, digital
391.4 (23.3) 11.6828 (0.0009) 107.5 (7.8) 0.0045 (0.0006) – 7.8 (1.5)
Annual,
40–64, ﬁlm
458.7 (21.7) 11.6819 (0.0010) 174.8 (8.2) 0.0036 (0.0004) – 6.5 (1.0)
Annual,
50–64, ﬁlm
459.1 (22.3) 11.6843 (0.0011) 175.2 (8.0) 0.0060 (0.0006) – 9.0 (1.1)
Annual,
50–64, digital
459.7 (22.5) 11.6852 (0.0009) 175.8 (7.4) 0.0069 (0.0005) $81,666 10.5 (1.2)
Annual,
40–64, digital
470.2 (23.0) 11.6847 (0.0011) 186.3 (8.6) 0.0064 (0.0006) – 10.3 (1.3)
Standard reimbursement for digital and ﬁlm mammography
No screening,
40–64
283.9 (16.1) 11.6783 (0.0010)
Biennial,
40–64, ﬁlm
383.7 (20.6) 11.6813 (0.0012) 99.8 (8.6) 0.0030 (0.0005) – 6.2 (1.3)
Biennial,
50–64, ﬁlm
384.6 (22.2) 11.6836 (0.0011) 100.7 (7.7) 0.0053 (0.0004) $18,999 7.8 (1.3)
Annual,
40–64, ﬁlm
458.7 (21.7) 11.6819 (0.0010) 174.8 (8.2) 0.0036 (0.0004) – 6.5 (1.0)
Annual,
50–64, ﬁlm
459.1 (22.3) 11.6843 (0.0011) 175.2 (8.0) 0.0060 (0.0006) $106,428 9.0 (1.1)
Biennial,
40–64, digital
474.4 (21.9) 11.6828 (0.0009) 190.5 (8.6) 0.0045 (0.0006) – 8.6 (1.4)
Biennial,
50–64, digital
476.0 (23.6) 11.6843 (0.0010) 192.1 (8.7) 0.0060 (0.0005) – 7.8 (1.5)
Annual,
50–64, digital
621.4 (21.7) 11.6852 (0.0009) 337.5 (8.6) 0.0069 (0.0005) $180,333 10.5 (1.2)
Annual,
40–64, digital
629.9 (20.9) 11.6847 (0.0011) 346.0 (8.8) 0.0064 (0.0006) – 10.3 (1.3)
Notes. All screening strategies are compared on the basis that an equal number of women (56%‡ of the cohort) receive screening in every
strategy. Results shown for equal and standard Medi-Cal reimbursement rates for digital and ﬁlm mammography (standard error of 60
simulation rounds).
CE, cost-effectiveness.
* Fifteen-year costs include screening, diagnosis, and treatment costs for the initial 5 y, and additional treatment costs extending beyond 5 y
for cancers diagnosed during the 5-y program.
† Mortality reduction over 15 y for the breast cancers diagnosed during the 5-y program.
‡ Fifty-six percent is the proportion of women aged 50 to 64 y derived from the program claims data. In strategies starting screening from age
50 y, all women aged 50 to 64 y are assumed to receive screening service, and women aged 40 to 49 y receive none; in strategies starting
screening from age 40 y, 56% of the women aged 40 to 64 y receive screening and the remaining 44% receive none.
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perform slightly better in younger women [6]. Digital mam-
mography adds less than a million dollars to 5-year program
costs when reimbursed at the Medi-Cal ﬁlm mammography
rate, because of additional diagnostic testing resulting
from its higher sensitivity. In 2014, after AB 359 expires,
coverage of digital mammography at the standard Medi-Calreimbursement rate would require a substantial budget
increase or a reduction in the number of women screened.
The cost per additional life-year gained for digital mammog-
raphy under standard reimbursement is well above the range
generally considered cost-effective, and our ﬁndings are con-
sistent with those of a US population-based microsimulation
model [37].
Standard MediCal Reimbursement Rate
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Fig. 2 – Incremental days of life gained and incremental costs for all evaluated screening strategies in the base-case analysis
under equal and standard Medi-Cal reimbursement for digital mammography. An, annual; Bi, biennial; D, digital; F, ﬁlm.
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nature of the data used to inform the model. We assumed that
women in the cohort were beginning screening mammography
and continued in the program throughout the 5-year period that
the policy was modeled. In reality, women are constantly gaining
and losing eligibility for the program and may not follow screen-
ing recommendations. However, sensitivity analyses supported
the relative cost-effectiveness of providing biennial screening
even in situations of poor adherence. The average screening
interval for women in the EWC program was 17 months, falling
between the intervals in the model. Similarly, the comparison of
adopting either purely digital mammography or purely ﬁlm
mammography does not reﬂect reality because the accessibility
of mammography technology varies geographically. Neverthe-
less, comparing two pure strategies is useful in distinguishing
their potential overall costs and effects on breast cancer out-
comes. Modeling these variables to more closely match the real
world would have required a much more complex model and a
longer time frame, reducing the policy relevance of the ﬁndings.
Because of a lack of utility data speciﬁc to the program clients or
to the multiple health states in the model, we opted to report
unadjusted life-years as the main outcome. This meant that the
impact of false-positive results (more common in women aged
40-49 years) on quality of life in terms of both physical harms of
testing and psychological harms of false positives was not
considered. Life-years are also a relatively straightforward metric
for policymakers. Analysis of the EWC program claims data
added greatly to the speciﬁcity of our model but was also limited
by the lack of data on diagnostic test outcomes. Despite these
limitations, the model calibrated remarkably well to program
breast cancer outcomes.
How did our ﬁndings inform EWC program policy? The time
elapsed from the inception of project funding to project comple-
tion was 18 months. Although this seemed a short time in the
academic environment, events overtook our work and required
changes to the model. Some program policy decisions were made
before the ﬁnal results of the model were available. At the
project’s inception in 2009, women 40 years and older who met
the EWC program criteria were eligible to enroll. Major cuts in the
program were made at the end of 2009 because of increased
demand for services and declining state revenues. Legislation
proposed to restore program funding was vetoed by GovernorSchwarzenegger. The California Department of Public Health
suspended “all new enrollments for breast cancer screening
services … and change[d] the eligibility age for breast cancer
screening services to 50 years of age or older” [38]. This change in
eligibility age was conﬁrmed by our analysis as a cost-effective
strategy. Because of concerns by state legislators about
the program policy changes, funding was subsequently increased
and after some restructuring, the program reopened to
new clients and restored eligibility at age 40 years for mammog-
raphy screening. Because of budget limitations, the program
has continued to reach only a portion of the eligible
population.
The contrasting ﬁndings of our model with restrictions on the
number of eligible women screened by the program with those of
the conventional model in which no limits were imposed illus-
trate the challenge for public health programs in applying the
results of conventional CEA to policy. The objective of conven-
tional CEA to maximize the health beneﬁt obtained based on the
cost per individual does not account for the limited budgets of
public programs and the need to consider the opportunity cost of
each policy decision [39,40].
Timeliness is an important issue limiting the application of
CEA. Historically, cost-effectiveness models have been published
too late to inﬂuence health policy decisions [5]. Policy options
that were feasible and sensible when an analysis was designed
may become unworkable under shifting political or budgetary
contexts. Furthermore, models constructed for one policy context
or health care system may not be applicable to another. Program
cost-effectiveness is only one consideration of many in the policy
arena. Despite the barriers to implementing CEA, researchers and
policy analysts continue to advocate for its integration into
health care policy formulation [41]. These challenges underscore
the importance of ﬂexibility, speed, and dissemination to
increase the relevance and usefulness of CEA models to inform
health policy.
The ongoing state budget shortfall in California continues to
challenge public health safety net programs. Simultaneously, the
number of women eligible for the EWC program has increased
over time consequent to increased unemployment and loss of
insurance coverage [42]. Implementation of mandatory coverage
for preventive services under the Affordable Care Act may reduce
the demand for EWC program services among underinsured
Table 3 – One-way sensitivity analysis of base-case model, with assumption of equal reimbursement for ﬁlm
and digital mammography.
Variables Base-case
values
Range ICER
* ($ per life-year gain)
Biennial, 50–64,
digital
Annual, 50–64,
digital
Base case 17,050 81,666
Cost of screening mammography ($) 66.8 53.4 12,596 59,423
80.2 32,611 122,950
Costs of breast cancer years 1–10 Year-speciﬁc 0.8  baseline 16,412 75,958
1.2  baseline 22,314 103,879
Prevalence of breast cancer, 40–49 y (%) 0.302 0.242 17,050 81,666
0.362 17,050 81,666
Prevalence of breast cancer, 50–64 y (%) 0.357 0.286 37,143 145,433
0.428 10,913 65,333
Breast cancer incidence rate Age-speciﬁc 0.8  baseline 23,122 133,734
1.2 baseline 13,295 68,333
Sensitivity of digital mammography, 50–64
y (%)
52.70 47.43 Dominated by “Bi, 50,
F”†
Dominated by “An, 50,
F”†
57.97 12,212 62.734
Speciﬁcity of digital mammography, 50–64
y (%)
92.50 87.88 Dominated by “Bi, 50,
F”†
118,800
97.13 8,714 46,634
Sensitivity of ﬁlm mammography, 50–64 y
(%)
49.70 44.73 17,050 81,666
55.67 Dominated by “Bi, 50,
F”†
Dominated by “An, 50,
F”†
Speciﬁcity of ﬁlm mammography, 50–64 y
(%)
92.30 87.69 17,050 81,666
96.92 Dominated by “Bi, 50,
F”†
Dominated by “An, 50,
F”†
Annual discount rate (%) 3.0 1.0 13,232 75,484
5.0 25,687 102,302
Mortality rate of breast cancer Year-speciﬁc 0.8  baseline 27,483 106,900
1.2 baseline 11,233 59,544
Adherence rate of screened subjects Perfectly
adherent
10% annual
dropout
15,188 92,183
30% annual
dropout
11,577 108,976
50% annual
dropout
9,788 121,465
Note. Parameters are varied 20%, except for sensitivities (10%), speciﬁcities (5%), and discount rate (1%–5%).
An, annual; Bi, biennial; D, digital; F, ﬁlm; ICER, incremental cost-effectiveness ratio.
 In case both mean cost and mean life year gains were not statistically different (a¼5%) with the base-case values, the basecase ICERs were
reported
† Dominance under certain scenarios indicates its moving away from the efﬁciency frontier. Strategy “An, 50, D” was compared with the
adjacent cost-effective but less-costly strategy on the efﬁciency frontier, which is “Bi, 50, D” or the strategy replacing “Bi, 50, D” if “Dominated
by” was stated.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 3 2 – 9 4 1940women and shift their costs of breast cancer screening to private
and public insurance programs; however, some women in Cal-
ifornia will not be affected by the Affordable Care Act and will
continue to require safety net assistance for access to breast
cancer screening. The challenges of allocating limited resources
to health care programs are widespread, and modeling the
potential outcomes and costs of alternative policy choices pro-
vides important information to inform decision making. Engaging
policymakers in structuring models, selecting inputs, deﬁning
relevant model outcomes, and viewing results will make CEA
more relevant to health care policy decision making, and may
ultimately result in more effective utilization of safety net and
other health care resources. Source of ﬁnancial support: Funding
was provided by the California Program on Access to Care (CPAC),School of Public Health, UC Berkeley, in cooperation with the
University of California, Ofﬁce of the President. CPAC had no
inﬂuence on the design and conduct of the study or the content
of the manuscript. The authors’ views and recommendations do
not necessarily represent those of the CPAC, the School of Public
Health, UC Berkeley, the Regents of the University of California,
or the California Department of Public Health.Supplemental Materials
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